{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T15:13:37Z","timestamp":1788880417180,"version":"build-2803163510"},"reference-count":100,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:00:00Z","timestamp":1784073600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000265","name":"UK Research and Innovation Medical Research Council","doi-asserted-by":"publisher","award":["MR\/X008029\/1"],"award-info":[{"award-number":["MR\/X008029\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008164","name":"Muscular Dystrophy UK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008164","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011724","name":"Muscular Dystrophy UK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011724","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy Nucleic Acids"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.omtn.2026.103017","type":"journal-article","created":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T23:18:05Z","timestamp":1784330285000},"page":"103017","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Timing matters: Exon skipping therapy is most effective when initiated early in a mouse model of Duchenne muscular dystrophy"],"prefix":"10.1016","volume":"37","author":[{"given":"Sofia","family":"Stenler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junyu","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tirsa L.E.","family":"van Westering","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna M.L.","family":"Coenen-Stass","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6307-0482","authenticated-orcid":false,"given":"Yahya","family":"Jad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaarel","family":"Krjut\u0161kov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samir","family":"EL Andaloussi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5436-6011","authenticated-orcid":false,"given":"Matthew J.A.","family":"Wood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3313-7631","authenticated-orcid":false,"given":"Thomas C.","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omtn.2026.103017_bib1","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/0092-8674(87)90579-4","article-title":"Dystrophin: The protein product of the duchenne muscular dystrophy locus","volume":"51","author":"Hoffman","year":"1987","journal-title":"Cell"},{"key":"10.1016\/j.omtn.2026.103017_bib2","doi-asserted-by":"crossref","first-page":"3710","DOI":"10.1073\/pnas.90.8.3710","article-title":"Dystrophin protects the sarcolemma from stresses developed during muscle contraction","volume":"90","author":"Petrof","year":"1993","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omtn.2026.103017_bib3","first-page":"83","article-title":"Autopsy analyses of the muscular dystrophies","volume":"40","author":"Moriuchi","year":"1993","journal-title":"Tokushima J. Exp. Med."},{"key":"10.1016\/j.omtn.2026.103017_bib4","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1016\/j.amjcard.2016.01.031","article-title":"Relation of Cardiac Dysfunction to Rhythm Abnormalities in Patients With Duchenne or Becker Muscular Dystrophies","volume":"117","author":"Chiang","year":"2016","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.omtn.2026.103017_bib5","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.nmd.2010.09.006","article-title":"Duchenne muscular dystrophy: Survival by cardio-respiratory interventions","volume":"21","author":"Ishikawa","year":"2011","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.omtn.2026.103017_bib6","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S1474-4422(18)30024-3","article-title":"Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management","volume":"17","author":"Birnkrant","year":"2018","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.omtn.2026.103017_bib7","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S1474-4422(18)30025-5","article-title":"Diagnosis and management of Duchenne muscular dystrophy, part 2: respiratory, cardiac, bone health, and orthopaedic management","volume":"17","author":"Birnkrant","year":"2018","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.omtn.2026.103017_bib8","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/S1474-4422(18)30026-7","article-title":"Diagnosis and management of Duchenne muscular dystrophy, part 3: primary care, emergency management, psychosocial care, and transitions of care across the lifespan","volume":"17","author":"Birnkrant","year":"2018","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.omtn.2026.103017_bib9","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1136\/jnnp-2012-303902","article-title":"Long-term benefits and adverse effects of intermittent versus daily glucocorticoids in boys with Duchenne muscular dystrophy","volume":"84","author":"Ricotti","year":"2013","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.omtn.2026.103017_bib10","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1177\/0883073814558120","article-title":"Corticosteroid Treatments in Males With Duchenne Muscular Dystrophy: Treatment Duration and Time to Loss of Ambulation","volume":"30","author":"Kim","year":"2015","journal-title":"J. Child Neurol."},{"key":"10.1016\/j.omtn.2026.103017_bib11","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/s13023-021-01758-9","article-title":"Standard of care versus new-wave corticosteroids in the treatment of Duchenne muscular dystrophy: Can we do better?","volume":"16","author":"Kourakis","year":"2021","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.omtn.2026.103017_bib12","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/s41573-023-00775-6","article-title":"Therapeutic approaches for Duchenne muscular dystrophy","volume":"22","author":"Roberts","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.omtn.2026.103017_bib13","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1080\/15476286.2021.1874161","article-title":"Molecular correction of Duchenne muscular dystrophy by splice modulation and gene editing","volume":"18","author":"Hanson","year":"2021","journal-title":"RNA Biol."},{"key":"10.1016\/j.omtn.2026.103017_bib14","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/s41573-020-0075-7","article-title":"Advances in oligonucleotide drug delivery","volume":"19","author":"Roberts","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.omtn.2026.103017_bib15","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1002\/humu.22758","article-title":"The TREAT-NMD DMD global database: Analysis of more than 7,000 duchenne muscular dystrophy mutations","volume":"36","author":"Bladen","year":"2015","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.omtn.2026.103017_bib16","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s10974-024-09688-2","article-title":"Progress and prospects in antisense oligonucleotide-mediated exon skipping therapies for Duchenne muscular dystrophy","volume":"46","author":"Chwalenia","year":"2025","journal-title":"J. Muscle Res. Cell Motil."},{"key":"10.1016\/j.omtn.2026.103017_bib17","doi-asserted-by":"crossref","first-page":"e2146","DOI":"10.1212\/WNL.0000000000005680","article-title":"Eteplirsen treatment for Duchenne muscular dystrophy: Exon skipping and dystrophin production","volume":"90","author":"Charleston","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.omtn.2026.103017_bib18","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1007\/s40265-021-01512-2","article-title":"Casimersen: First Approval","volume":"81","author":"Shirley","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.omtn.2026.103017_bib19","doi-asserted-by":"crossref","first-page":"eaan0713","DOI":"10.1126\/scitranslmed.aan0713","article-title":"Systemic administration of the antisense oligonucleotide NS-065\/NCNP-01 for skipping of exon 53 in patients with Duchenne muscular dystrophy","volume":"10","author":"Komaki","year":"2018","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.omtn.2026.103017_bib20","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1089\/nat.2021.0043","article-title":"Long-Term Safety and Efficacy Data of Golodirsen in Ambulatory Patients with Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping: A First-in-human, Multicenter, Two-Part, Open-Label, Phase 1\/2 Trial","volume":"32","author":"Servais","year":"2022","journal-title":"Nucleic Acid Ther."},{"key":"10.1016\/j.omtn.2026.103017_bib21","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/nbt.3819","article-title":"Response to \u201cRailroading at the FDA\u201d","volume":"35","author":"Muntoni","year":"2017","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.omtn.2026.103017_bib22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/nat.2016.0657","article-title":"FDA Approves Eteplirsen for Duchenne Muscular Dystrophy: The Next Chapter in the Eteplirsen Saga","volume":"27","author":"Aartsma-Rus","year":"2017","journal-title":"Nucleic Acid Ther."},{"key":"10.1016\/j.omtn.2026.103017_bib23","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1038\/nrneurol.2016.180","article-title":"Eteplirsen therapy for Duchenne muscular dystrophy: skipping to the front of the line","volume":"12","author":"Dowling","year":"2016","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.omtn.2026.103017_bib24","unstructured":"FDA Briefing Document. Peripheral and Central Nervous System Drugs Advisory Committee Meeting, January 22, 2016, NDA 206488, Eteplirsen. 2016. https:\/\/www.fda.gov\/files\/advisory%20committees\/published\/FDA-Briefing-Information-for-the-January-22--2016-Meeting-of-the-Peripheral-and-Central-Nervous-System-Drugs-Advisory-Committee.pdf."},{"key":"10.1016\/j.omtn.2026.103017_bib25","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1038\/nbt.3733","article-title":"Railroading at the FDA","volume":"34","year":"2016","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.omtn.2026.103017_bib26","doi-asserted-by":"crossref","first-page":"469","DOI":"10.3233\/JND-200548","article-title":"Comparison of Long-term Ambulatory Function in Patients with Duchenne Muscular Dystrophy Treated with Eteplirsen and Matched Natural History Controls","volume":"8","author":"Mendell","year":"2021","journal-title":"J. Neuromuscul. Dis."},{"key":"10.1016\/j.omtn.2026.103017_bib27","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1007\/s40265-023-01929-x","article-title":"Delandistrogene Moxeparvovec: First Approval","volume":"83","author":"Hoy","year":"2023","journal-title":"Drugs"},{"key":"10.1016\/j.omtn.2026.103017_bib28","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1038\/s41591-024-03304-z","article-title":"AAV gene therapy for Duchenne muscular dystrophy: the EMBARK phase 3 randomized trial","volume":"31","author":"Mendell","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.omtn.2026.103017_bib29","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1038\/s41434-025-00561-6","article-title":"AAV microdystrophin gene replacement therapy for Duchenne muscular dystrophy: progress and prospects","volume":"32","author":"Chwalenia","year":"2025","journal-title":"Gene Ther."},{"key":"10.1016\/j.omtn.2026.103017_bib30","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1038\/gt.2009.120","article-title":"Dose-dependent restoration of dystrophin expression in cardiac muscle of dystrophic mice by systemically delivered morpholino","volume":"17","author":"Wu","year":"2010","journal-title":"Gene Ther."},{"key":"10.1016\/j.omtn.2026.103017_bib31","doi-asserted-by":"crossref","first-page":"e38","DOI":"10.1038\/mtna.2012.30","article-title":"Pip6-PMO, A New Generation of Peptide-oligonucleotide Conjugates With Improved Cardiac Exon Skipping Activity for DMD Treatment","volume":"1","author":"Betts","year":"2012","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.omtn.2026.103017_bib32","doi-asserted-by":"crossref","first-page":"8986","DOI":"10.1038\/srep08986","article-title":"Prevention of exercised induced cardiomyopathy following Pip-PMO treatment in dystrophic mdx mice","volume":"5","author":"Betts","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.omtn.2026.103017_bib33","doi-asserted-by":"crossref","first-page":"9500","DOI":"10.1093\/nar\/gkt724","article-title":"Extracellular microRNAs are dynamic non-vesicular biomarkers of muscle turnover","volume":"41","author":"Roberts","year":"2013","journal-title":"Nucl. Acids Res."},{"key":"10.1016\/j.omtn.2026.103017_bib34","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1038\/mt.2011.79","article-title":"Pip5 transduction peptides direct high efficiency oligonucleotide-mediated dystrophin exon skipping in heart and phenotypic correction in mdx mice","volume":"19","author":"Yin","year":"2011","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtn.2026.103017_bib35","doi-asserted-by":"crossref","first-page":"4364","DOI":"10.1021\/acs.nanolett.5b00490","article-title":"Self-Assembly into Nanoparticles Is Essential for Receptor Mediated Uptake of Therapeutic Antisense Oligonucleotides","volume":"15","author":"Ezzat","year":"2015","journal-title":"Nano Lett."},{"key":"10.1016\/j.omtn.2026.103017_bib36","doi-asserted-by":"crossref","first-page":"3207","DOI":"10.1093\/nar\/gkt1220","article-title":"Cellular trafficking determines the exon skipping activity of Pip6a-PMO in mdx skeletal and cardiac muscle cells","volume":"42","author":"Lehto","year":"2014","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.omtn.2026.103017_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.nmd.2022.07.349","article-title":"P.194 Development of a novel, EEV-Conjugated PMO for Duchenne muscular dystrophy","volume":"32","author":"Kreher","year":"2022","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.omtn.2026.103017_bib38","unstructured":"PepGen Reports Positive Data from Phase 1 Trial of PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy | PepGen https:\/\/investors.pepgen.com\/news-releases\/news-release-details\/pepgen-reports-positive-data-phase-1-trial-pgn-edo51-treatment\/."},{"key":"10.1016\/j.omtn.2026.103017_bib39","doi-asserted-by":"crossref","first-page":"2296","DOI":"10.1016\/j.bbamem.2010.02.012","article-title":"Morpholinos and their peptide conjugates: Therapeutic promise and challenge for Duchenne muscular dystrophy","volume":"1798","author":"Moulton","year":"2010","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.omtn.2026.103017_bib40","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1021\/bc070060v","article-title":"Pharmacokinetics, biodistribution, stability and toxicity of a cell-penetrating peptide-morpholino oligomer conjugate","volume":"18","author":"Amantana","year":"2007","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.omtn.2026.103017_bib41","unstructured":"Community Letter: Update SRP-5051 Program | Sarepta Therapeutics https:\/\/www.sarepta.com\/community-letter-update-srp-5051-program."},{"key":"10.1016\/j.omtn.2026.103017_bib42","unstructured":"Sarepta Therapeutics Announces Third Quarter 2024 Financial Results and Recent Corporate Developments | Sarepta Therapeutics, Inc. https:\/\/investorrelations.sarepta.com\/news-releases\/news-release-details\/sarepta-therapeutics-announces-third-quarter-2024-financial."},{"key":"10.1016\/j.omtn.2026.103017_bib43","series-title":"PepGen Announces Discontinuation of PGN-EDO51 Development","year":"2025"},{"key":"10.1016\/j.omtn.2026.103017_bib44","unstructured":"Avidity Biosciences Announces Phase 1\/2 EXPLORE44\u2122 Trial of AOC 1044 for Duchenne Muscular Dystrophy Mutations Amenable to Exon 44 Skipping Investors | Avidity Biosciences. https:\/\/aviditybiosciences.investorroom.com\/2022-10-11-Avidity-Biosciences-Announces-Phase-1-2-EXPLORE44-TM-Trial-of-AOC-1044-for-Duchenne-Muscular-Dystrophy-Mutations-Amenable-to-Exon-44-Skipping."},{"key":"10.1016\/j.omtn.2026.103017_bib45","doi-asserted-by":"crossref","first-page":"11401","DOI":"10.1093\/nar\/gkac641","article-title":"Enhanced exon skipping and prolonged dystrophin restoration achieved by TfR1-targeted delivery of antisense oligonucleotide using FORCE conjugation in mdx mice","volume":"50","author":"Desjardins","year":"2022","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.omtn.2026.103017_bib46","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1073\/pnas.81.4.1189","article-title":"X chromosome-linked muscular dystrophy (mdx) in the mouse","volume":"81","author":"Bulfield","year":"1984","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omtn.2026.103017_bib47","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1126\/science.2662404","article-title":"The molecular basis of muscular dystrophy in the mdx mouse: a point mutation","volume":"244","author":"Sicinski","year":"1989","journal-title":"Science"},{"key":"10.1016\/j.omtn.2026.103017_bib48","doi-asserted-by":"crossref","first-page":"6756","DOI":"10.1093\/hmg\/ddv381","article-title":"Multi-level omics analysis in a murine model of dystrophin loss and therapeutic restoration","volume":"24","author":"Roberts","year":"2015","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.omtn.2026.103017_bib49","doi-asserted-by":"crossref","first-page":"e39","DOI":"10.1038\/mtna.2012.26","article-title":"Expression Analysis in Multiple Muscle Groups and Serum Reveals Complexity in the MicroRNA Transcriptome of the mdx Mouse with Implications for Therapy","volume":"1","author":"Roberts","year":"2012","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.omtn.2026.103017_bib50","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.omtn.2018.08.005","article-title":"Comprehensive RNA-Sequencing Analysis in Serum and Muscle Reveals Novel Small RNA Signatures with Biomarker Potential for DMD","volume":"13","author":"Coenen-Stass","year":"2018","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.omtn.2026.103017_bib51","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1074\/mcp.RA120.002345","article-title":"Mutation-independent Proteomic Signatures of Pathological Progression in Murine Models of Duchenne Muscular Dystrophy","volume":"19","author":"van Westering","year":"2020","journal-title":"Mol. Cell. Proteomics"},{"key":"10.1016\/j.omtn.2026.103017_bib52","doi-asserted-by":"crossref","first-page":"4225","DOI":"10.1093\/hmg\/ddv155","article-title":"How much dystrophin is enough: the physiological consequences of different levels of dystrophin in the mdx mouse","volume":"24","author":"Godfrey","year":"2015","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.omtn.2026.103017_bib53","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1136\/jnnp-2013-306350","article-title":"Dystrophin levels and clinical severity in Becker muscular dystrophy patients","volume":"85","author":"van den Bergen","year":"2014","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.omtn.2026.103017_bib54","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1212\/WNL.39.8.1011","article-title":"Improved diagnosis of Becker muscular dystrophy by dystrophin testing","volume":"39","author":"Hoffman","year":"1989","journal-title":"Neurology"},{"key":"10.1016\/j.omtn.2026.103017_bib55","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1038\/343180a0","article-title":"Very mild muscular dystrophy associated with the deletion of 46% of dystrophin","volume":"343","author":"England","year":"1990","journal-title":"Nature"},{"key":"10.1016\/j.omtn.2026.103017_bib56","series-title":"Nationwide Children\u2019s Announces Restoration of Full-Length Dystrophin Using Dup 2 Gene Therapy Approach","year":"2022"},{"key":"10.1016\/j.omtn.2026.103017_bib57","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/s41586-024-07710-8","article-title":"Split intein-mediated protein trans-splicing to express large dystrophins","volume":"632","author":"Tasfaout","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.omtn.2026.103017_bib58","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1126\/science.adp8179","article-title":"Ribozyme-activated mRNA trans-ligation enables large gene delivery to treat muscular dystrophies","volume":"386","author":"Lindley","year":"2024","journal-title":"Science"},{"key":"10.1016\/j.omtn.2026.103017_bib59","doi-asserted-by":"crossref","first-page":"6141","DOI":"10.1038\/s41467-024-50569-6","article-title":"Systemic delivery of full-length dystrophin in Duchenne muscular dystrophy mice","volume":"15","author":"Zhou","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omtn.2026.103017_bib60","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/s41598-017-00152-5","article-title":"Lentiviral vectors can be used for full-length dystrophin gene therapy","volume":"7","author":"Counsell","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.omtn.2026.103017_bib61","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/S0960-8966(97)00054-0","article-title":"Gene transfer to muscle using herpes simplex virus-based vectors","volume":"7","author":"Huard","year":"1997","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.omtn.2026.103017_bib62","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1089\/104303404772679959","article-title":"Sustained improvement of muscle function one year after full-length dystrophin gene transfer into mdx mice by a gutted helper-dependent adenoviral vector","volume":"15","author":"Dudley","year":"2004","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omtn.2026.103017_bib63","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1002\/jcsm.12506","article-title":"Uniform sarcolemmal dystrophin expression is required to prevent extracellular microRNA release and improve dystrophic pathology","volume":"11","author":"van Westering","year":"2020","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.omtn.2026.103017_bib64","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/j.omtn.2022.08.033","article-title":"Exon skipping induces uniform dystrophin rescue with dose-dependent restoration of serum miRNA biomarkers and muscle biophysical properties","volume":"29","author":"Chwalenia","year":"2022","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.omtn.2026.103017_bib65","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.omtn.2022.10.010","article-title":"Non-uniform dystrophin re-expression after CRISPR-mediated exon excision in the dystrophin\/utrophin double-knockout mouse model of DMD","volume":"30","author":"Hanson","year":"2022","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.omtn.2026.103017_bib66","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2206324120","article-title":"Dystrophin myonuclear domain restoration governs treatment efficacy in dystrophic muscle","volume":"120","author":"Morin","year":"2023","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omtn.2026.103017_bib67","doi-asserted-by":"crossref","DOI":"10.1002\/jcsm.70284","article-title":"Myonuclear Domain-Associated and Central Nucleation-Dependent Spatial Restriction of Dystrophin Protein Expression","volume":"17","author":"Chwalenia","year":"2026","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.omtn.2026.103017_bib68","doi-asserted-by":"crossref","DOI":"10.1038\/srep17014","article-title":"Identification of novel, therapy-responsive protein biomarkers in a mouse model of Duchenne muscular dystrophy by aptamer-based serum proteomics","volume":"5","author":"Coenen-Stass","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.omtn.2026.103017_bib69","doi-asserted-by":"crossref","first-page":"3960","DOI":"10.1093\/hmg\/ddw237","article-title":"Selective release of muscle-specific, extracellular microRNAs during myogenic differentiation","volume":"25","author":"Coenen-Stass","year":"2016","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.omtn.2026.103017_bib70","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1126\/science.3347839","article-title":"Expression of the murine Duchenne muscular dystrophy gene in muscle and brain","volume":"239","author":"Chamberlain","year":"1988","journal-title":"Science"},{"key":"10.1016\/j.omtn.2026.103017_bib71","doi-asserted-by":"crossref","first-page":"15000","DOI":"10.1073\/pnas.192571199","article-title":"Gene expression comparison of biopsies from Duchenne muscular dystrophy (DMD) and normal skeletal muscle","volume":"99","author":"Haslett","year":"2002","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omtn.2026.103017_bib72","doi-asserted-by":"crossref","first-page":"16456","DOI":"10.1073\/pnas.1910456117","article-title":"Premature termination codons in the DMD gene cause reduced local mRNA synthesis","volume":"117","author":"Garc\u00eda-Rodr\u00edguez","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omtn.2026.103017_bib73","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1093\/nar\/24.15.3059","article-title":"Stability of the human dystrophin transcript in muscle","volume":"24","author":"Tennyson","year":"1996","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.omtn.2026.103017_bib74","doi-asserted-by":"crossref","first-page":"4909","DOI":"10.1096\/fj.13-232025","article-title":"DMD transcript imbalance determines dystrophin levels","volume":"27","author":"Spitali","year":"2013","journal-title":"FASEB J."},{"key":"10.1016\/j.omtn.2026.103017_bib75","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1101\/gr.133744.111","article-title":"Detecting differential usage of exons from RNA-seq data","volume":"22","author":"Anders","year":"2012","journal-title":"Genome Res."},{"key":"10.1016\/j.omtn.2026.103017_bib76","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.omtn.2022.11.017","article-title":"Histone deacetylase inhibitors improve antisense-mediated exon-skipping efficacy in mdx mice","volume":"30","author":"Bizot","year":"2022","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.omtn.2026.103017_bib77","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2023.1152576","article-title":"Indicators of increased ER stress and UPR in aged D2-mdx and human dystrophic skeletal muscles","volume":"14","author":"Krishna","year":"2023","journal-title":"Front. Physiol."},{"key":"10.1016\/j.omtn.2026.103017_bib78","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.freeradbiomed.2016.08.017","article-title":"Effects of muscular dystrophy, exercise and blocking activin receptor IIB ligands on the unfolded protein response and oxidative stress","volume":"99","author":"Hulmi","year":"2016","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.omtn.2026.103017_bib79","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2021.638983","article-title":"The Role of Autophagy in Skeletal Muscle Diseases","volume":"12","author":"Xia","year":"2021","journal-title":"Front. Physiol."},{"key":"10.1016\/j.omtn.2026.103017_bib80","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1038\/embor.2010.208","article-title":"miR-31 modulates dystrophin expression: new implications for Duchenne muscular dystrophy therapy","volume":"12","author":"Cacchiarelli","year":"2011","journal-title":"EMBO Rep."},{"key":"10.1016\/j.omtn.2026.103017_bib81","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1016\/j.celrep.2015.07.066","article-title":"TNF-\u03b1-Induced microRNAs Control Dystrophin Expression in Becker Muscular Dystrophy","volume":"12","author":"Fiorillo","year":"2015","journal-title":"Cell Rep."},{"key":"10.1016\/j.omtn.2026.103017_bib82","doi-asserted-by":"crossref","first-page":"3335","DOI":"10.1096\/fj.08-128579","article-title":"Common micro-RNA signature in skeletal muscle damage and regeneration induced by Duchenne muscular dystrophy and acute ischemia","volume":"23","author":"Greco","year":"2009","journal-title":"FASEB J."},{"key":"10.1016\/j.omtn.2026.103017_bib83","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1247\/csf.08022","article-title":"MicroRNA-206 is highly expressed in newly formed muscle fibers: implications regarding potential for muscle regeneration and maturation in muscular dystrophy","volume":"33","author":"Yuasa","year":"2008","journal-title":"Cell Struct. Funct."},{"key":"10.1016\/j.omtn.2026.103017_bib84","doi-asserted-by":"crossref","first-page":"9674","DOI":"10.1038\/s41598-022-13405-9","article-title":"Muscle regeneration affects Adeno Associated Virus 1 mediated transgene transcription","volume":"12","author":"Mollard","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.omtn.2026.103017_bib85","doi-asserted-by":"crossref","DOI":"10.1038\/mtm.2015.10","article-title":"Short-lived recombinant adeno-associated virus transgene expression in dystrophic muscle is associated with oxidative damage to transgene mRNA","volume":"2","author":"Dupont","year":"2015","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omtn.2026.103017_bib86","article-title":"Investigating Synthetic Oligonucleotide Targeting of Mir31 in Duchenne Muscular Dystrophy","volume":"8","author":"Hildyard","year":"2016","journal-title":"PLoS Curr."},{"key":"10.1016\/j.omtn.2026.103017_bib87","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.molmed.2017.09.002","article-title":"Biomarker Potential of Extracellular miRNAs in Duchenne Muscular Dystrophy","volume":"23","author":"Coenen-Stass","year":"2017","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.omtn.2026.103017_bib88","doi-asserted-by":"crossref","first-page":"3017","DOI":"10.1016\/S0140-6736(16)31408-8","article-title":"Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study","volume":"388","author":"Finkel","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.omtn.2026.103017_bib89","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/mus.27532","article-title":"Time to diagnosis of Duchenne muscular dystrophy remains unchanged: Findings from the Muscular Dystrophy Surveillance, Tracking, and Research Network, 2000-2015","volume":"66","author":"Thomas","year":"2022","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.omtn.2026.103017_bib90","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s12519-019-00242-6","article-title":"Progress in treatment and newborn screening for Duchenne muscular dystrophy and spinal muscular atrophy","volume":"15","author":"Ke","year":"2019","journal-title":"World J. Pediatr."},{"key":"10.1016\/j.omtn.2026.103017_bib91","unstructured":"Sarepta Therapeutics Announces Voluntary Pause of ELEVIDYS Shipments in the U.S. | Sarepta Therapeutics, Inc. https:\/\/investorrelations.sarepta.com\/news-releases\/news-release-details\/sarepta-therapeutics-announces-voluntary-pause-elevidys."},{"key":"10.1016\/j.omtn.2026.103017_bib92","doi-asserted-by":"crossref","first-page":"3555","DOI":"10.1093\/hmg\/ddw201","article-title":"Antisense pre-treatment increases gene therapy efficacy in dystrophic muscles","volume":"25","author":"Peccate","year":"2016","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.omtn.2026.103017_bib93","doi-asserted-by":"crossref","first-page":"3047","DOI":"10.1093\/bioinformatics\/btw354","article-title":"MultiQC: summarize analysis results for multiple tools and samples in a single report","volume":"32","author":"Ewels","year":"2016","journal-title":"Bioinformatics"},{"key":"10.1016\/j.omtn.2026.103017_bib94","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1038\/nmeth.3317","article-title":"HISAT: a fast spliced aligner with low memory requirements","volume":"12","author":"Kim","year":"2015","journal-title":"Nat. Methods"},{"key":"10.1016\/j.omtn.2026.103017_bib95","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1093\/bioinformatics\/btp352","article-title":"The Sequence Alignment\/Map format and SAMtools","volume":"25","author":"Li","year":"2009","journal-title":"Bioinformatics"},{"key":"10.1016\/j.omtn.2026.103017_bib96","doi-asserted-by":"crossref","first-page":"D754","DOI":"10.1093\/nar\/gkx1098","article-title":"Ensembl 2018","volume":"46","author":"Zerbino","year":"2018","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.omtn.2026.103017_bib97","doi-asserted-by":"crossref","first-page":"W191","DOI":"10.1093\/nar\/gkz369","article-title":"g:Profiler: a web server for functional enrichment analysis and conversions of gene lists (2019 update)","volume":"47","author":"Raudvere","year":"2019","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.omtn.2026.103017_bib98","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0021800","article-title":"REVIGO summarizes and visualizes long lists of gene ontology terms","volume":"6","author":"Supek","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.omtn.2026.103017_bib99","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1089\/nat.2014.0528","article-title":"Development and Application of an Ultrasensitive Hybridization-Based ELISA Method for the Determination of Peptide-Conjugated Phosphorodiamidate Morpholino Oligonucleotides","volume":"25","author":"Burki","year":"2015","journal-title":"Nucleic Acid Ther."},{"key":"10.1016\/j.omtn.2026.103017_bib100","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1093\/nar\/29.9.e45","article-title":"A new mathematical model for relative quantification in real-time RT\u2013PCR","volume":"29","author":"Pfaffl","year":"2001","journal-title":"Nucleic Acids Res."}],"container-title":["Molecular Therapy Nucleic Acids"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162253126001885?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162253126001885?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T15:01:47Z","timestamp":1788879707000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2162253126001885"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":100,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S2162253126001885"],"URL":"https:\/\/doi.org\/10.1016\/j.omtn.2026.103017","relation":{},"ISSN":["2162-2531"],"issn-type":[{"value":"2162-2531","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Timing matters: Exon skipping therapy is most effective when initiated early in a mouse model of Duchenne muscular dystrophy","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy Nucleic Acids","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omtn.2026.103017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}],"article-number":"103017"}}